Caregiver Brochure
Resources
Download these helpful INQOVI resources:
Patient Brochure
Conversation Handbook for Nurses
Nurse Guide
Patient Access Brochure
Co-Pay Brochure
INQOVI Nurse Checklist
Pharmacy Guide
Community Oncologist Guide
Codes relating to the use of INQOVI
The diagnostic codes contained in this section are designed to provide important reimbursement information that will be helpful for your pharmacy when ordering INQOVI. ICD codes continually change, so it is recommended that you consult your ICD-10 code book or contact the payer for coding and billing guidance.
| Formulation | Packaging | NDC (11-digit format)* |
|---|---|---|
| 35 mg decitabine and 100 mg cedazuridine | 5-tablet blister pack | 64842-0727-09 |
*The National Drug Code (NDC) has been “zero-filled” to convert the 10-digit NDC to an 11-digit NDC that meets Centers for Medicare & Medicaid Services standards. The zero-fill location is indicated in bold. Check payer requirements for appropriate reporting of the NDC.
Please contact an authorized distributor or one of the specialty pharmacies listed on next page for the average wholesale price (AWP) and wholesale acquisition cost (WAC) pricing.
Diagnosis codes for Myelodysplastic Syndromes (MDS)
| ICD‑10‑CM | Description |
|---|---|
| D46.0 |
Refractory anemia without ring sideroblasts, so stated
Refractory anemia without sideroblasts, without excess of blasts |
| D46.1 | Refractory anemia with ring sideroblasts (RARS) |
| D46.2 | Refractory anemia with excess of blasts (RAEB) |
| D46.20 | Refractory anemia with excess of blasts, unspecified (RAEB NOS) |
| D46.21 | Refractory anemia with excess of blasts 1 (RAEB 1) |
| D46.22 | Refractory anemia with excess of blasts 2 (RAEB 2) |
| D46.A | Refractory cytopenia with multilineage dysplasia |
| D46.B | Refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD RS) |
| D46.C |
Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
Myelodysplastic syndrome with 5q deletion 5q minus syndrome NOS |
| D46.4 | Refractory anemia, unspecified |
| D46.Z | Other myelodysplastic syndromes (EXCLUDES chronic myelomonocytic leukemia [C93.1]) |
| D46.9 |
Myelodysplastic syndrome, unspecified
Myelodysplasia NOS |
AAPC. ICD-10-CM Expert 2020 for Providers & Facilities. American Academy of Professional Coders; 2020:505.
This information is not intended as coverage or coding advice and does not guarantee reimbursement. You should verify the appropriate reimbursement information for services or items you provide. Each health care professional is responsible for ensuring all coding is accurate and appropriate.
Diagnosis codes for Chronic Myelomonocytic Leukemia (CMML)
| ICD‑10‑CM | Description |
|---|---|
| C93.1 |
Chronic myelomonocytic leukemia
Chronic monocytic leukemia CMML-1 CMML-2 CMML with eosinophilia |
| C93.10 |
Chronic myelomonocytic leukemia not having achieved remission
Chronic myelomonocytic leukemia with failed remission Chronic myelomonocytic leukemia NOS |
| C93.11 | Chronic myelomonocytic leukemia, in remission |
| C93.12 | Chronic myelomonocytic leukemia, in relapse |
AAPC. ICD-10-CM Expert 2020 for Providers & Facilities. American Academy of Professional Coders; 2020:494.
INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Taiho Oncology Patient Support™ for you and your patients
Taiho Oncology Patient Support offers personalized services to help give patients, caregivers and healthcare professionals access to Taiho Oncology products. This includes insurance coverage determination and help with medication affordability. For more information, please visit or refer patients to TaihoPatientSupport.com.
Meeting the access needs of your patients
Getting
patients access to their medicine is an important step. Taiho Oncology Patient Support strives to make this process as simple as
possible.
Taiho Oncology Patient Support can assist with:
Insurance Coverage Support
- Benefits investigation
- Prior authorization assistance
- Appeals assistance
- Coordination of prescriptions with pharmacies
Patient Affordability Assistance*†
- $0 co-pay program enrollment for eligible commercially insured patients
- Patient assistance program designed to provide free medication to eligible patients who are uninsured or underinsured
- Referrals to third-party foundations for co-pay or other assistance based on eligibility and additional criteria
- Referrals to Medicare Part D Low-Income Subsidy (LIS)/Extra Help Program
Personalized Nurse Support‡
- One-on-one nurse educational support for patients, available via opt‑in
Taiho Oncology Patient Support Co-pay Program
Eligible, privately insured patients can enroll in the Taiho Oncology Patient Support Co-pay program, which may help reduce out-of-pocket expenses to $0 for their treatment with INQOVI tablets.
To determine patient eligibility, go to TaihoOncologyCopay.com or call 1-844-TAIHO-4U (1-844-824-4648).
Support starts with an easy-to-complete Enrollment Form that can be downloaded at TaihoPatientSupport.com/how-to-enroll.
To register or learn more, visit or refer patients to TaihoPatientSupport.com or call 1-844-TAIHO-4U (1-844-824-4648) Monday to Friday, 8 AM to 8 PM ET.
*Visit TaihoPatientSupport.com to see full eligibility criteria.
†Restrictions and eligibility: Offer valid in the US, Puerto Rico, and US territories only. Only valid for patients with private insurance. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefits plan, Tricare, or other federal or state programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program, this offer is not valid and the patient cannot use this offer. By presenting or accepting this benefit, patient and pharmacist agree not to submit claim for reimbursement under the above programs. Patient further agrees to comply with any and all terms of his or her health insurance contract requiring notification to his or her payer for the existence and/or value of this offer. It is illegal to or offer to sell, purchase, or trade this benefit. Maximum reimbursement limits apply; patient out-of-pocket expense may vary. Taiho Oncology, Inc. reserves the right to rescind, revoke or amend this offer at any time without notice.
‡If selected on the Patient Enrollment Form, a Nurse Navigator will be assigned to provide telephone support and will address general inquiries about INQOVI treatment.
The INQOVI Treatment Kit
A kit to help patients and caregivers with INQOVI treatment for MDS that includes:
1
A comprehensive patient brochure
2
Accompanying caregiver brochure
3
Blister pack opener
4
Health journal
5
Advocacy support brochure
Treatment kit is approximately 10.125 in x 11.125 in x 1.625 in.
Patient advocacy organizations
These organizations offer patients information, support, and community. Feel free to share the following resources with your patients:
The Myelodysplastic Syndromes (MDS) Foundation Inc.
Visit mds-foundation.org or call 1-800-MDS-0839 (1-800-637-0839)
The Aplastic Anemia and MDS International Foundation (AAMDSIF)
Visit aamds.org or call 1-800-747-2820
Important things to remember while patients are treated with INQOVI
-
INQOVI tablets can be substituted for IV decitabine, but not within a cycle.1
-
Patients should be closely monitored during treatment with INQOVI, especially during the early cycles.1
- Incidence of cytopenias was slightly higher with INQOVI during Cycle 1 compared to IV decitabine1,2
-
A response to INQOVI tablets may not be immediate. A complete or partial response may take longer than 4 cycles.1
-
Antiemetics (prior to each dose), growth factors, and anti-infective therapies can be administered for treatment or prophylaxis as appropriate.1